1例伊立替康致结肠癌患者急性肝损伤的药学监护

doi:10.19803/j.1672-8629.20240009

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 693-696.
DOI: 10.19803/j.1672-8629.20240009

1例伊立替康致结肠癌患者急性肝损伤的药学监护

林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳^*

上海市浦东新区公利医院临床药学部,上海200135

收稿日期:2024-01-04 出版日期:2024-06-15 发布日期:2024-06-18
通讯作者: ^*李文艳,女,硕士,主任药师,中药新药与临床药学。 E-mail:liwenyan_linda@163.com
作者简介:林彦馨,女,硕士,药师,临床药学。
基金资助:
上海市浦东新区卫生系统领先人才（PWRI2021-11）

Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan

LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan^*

Department of Clinical Pharmacy, Gongli Hospital of Pudong New Area in Shanghai, Shanghai 200135, China

Received:2024-01-04 Online:2024-06-15 Published:2024-06-18

摘要/Abstract

摘要： 目的探讨临床药师在肿瘤患者肝损伤治疗过程中的作用,为临床药师参与临床实践提供参考。方法临床药师参与1例结肠癌患者使用伊立替康致急性肝损伤的治疗过程,对导致患者急性肝损伤原因进行分析,通过RUCAM因果关系评估量表评估药物与肝损伤因果关系,调整保肝药物治疗方案。结果临床药师通过分析患者急性肝损伤与疾病和药物的相关性,及时为临床提供了保肝药物治疗方案的优化建议,对患者用药进行药学监护,经治疗患者肝功能有明显好转。结论临床药师对肿瘤化疗患者进行密切药学监护,有助于降低不良反应,优化药物治疗效果,提升临床合理用药水平。

关键词: 伊立替康, 肝损伤, 结肠癌, 药品不良反应, 药学监护, 临床药师

Abstract: Objective To explore the role of clinical pharmacists in the treatment of liver injury in tumor patients, and to provide reference for the involvement of clinical pharmacists in clinical practice. Methods Clinical pharmacists participated in the treatment of one case of acute liver injury caused by irinotecan in a colon cancer patient, analyzed the causes of acute liver injury, assessed the causal relationship between the drug and liver injury using the Roussel Uclaf Causality Assessment Method (RUCAM), and adjusted the treatment with liver-protecting drugs. Results By analyzing the correlation between acute liver injury and diseases and drugs, clinical pharmacists quickly recommended optimization of the treatment with liver-protecting drugs, and provided pharmaceutical care for the patient. After treatment, the patient’s liver function was significantly improved. Conclusion Prudent pharmacological monitoring of patients under chemotherapy by clinical pharmacists can help to reduce the incidence of adverse reactions, optimize the effect of drug therapy, and improve the level of rational clinical use of drugs.

Key words: irinotecan, liver injury, colon cancer, adverse drug reaction, pharmaceutical care, clinical pharmacist

中图分类号:

R994.11

林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.

LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan. Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20240009

https://www.zgywjj.com/CN/Y2024/V21/I6/693

参考文献

[1] YU SY, YAO Y.Expert Consensus on Prevention and Treatment of Cancer Drug-Related Liver Injury (肿瘤药物相关性肝损伤防治专家共识)[M]. Beijing: China Union Medical College Press, 2014.
[2] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association. Chinese guideline for diagnosis and management of drug - induced liver injury (2023 version)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2023, 31(4): 355-384.
[3] LI XY, TANG JT, MAO YM.Incidence and risk factors of drug-induced liver injury[J]. Liver international, 2022, 42(9): 1999-2014.
[4] Chinese College of Surgeons. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2023)[J]. Chinese Journal of Digestive Surgery(中华消化外科杂志), 2023, 22(1): 1-28.
[5] TURAL D, AKAR E, MEHMET AO, et al.Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma[J]. Journal of Cancer Research & Therapeutics, 2014, 10(3): 745-748.
[6] Chinese Medical Association.Guideline for primary care of drug-induced liver injury(2019)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(10): 868-875.
[7] DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al.Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines[J]. Hepatology international, 2021, 15(2): 258-282.
[8] ZENG D.Angelica Polysaccharide Alleviated Liver Injury Induced by 5-Fluorouracil by Regulating NRF2/HO-1 Signaling Pathway[D]. Chongqing Medical University, 2022.
[9] ZORZI D, LAURENT A, PAWLIK TM, et al.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases[J]. The British journal of surgery, 2007, 94(3): 274-286.
[10] WANG F, CHEN SC, CAO NY, et al.Effect of irinotecan combined with cetuximab on liver function and histology in patients with advanced colorectal cancer and liver metastasis[J]. Chinese Journal of Clinical Oncology and Rehabilitation(中国肿瘤临床与康复), 2016, 23(9): 1047-1050.
[11] HAN J, LIU J, YU Z, et al.Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China[J]. British Medical Journal Open, 2023, 13(6):e069794.
[12] LI J, CHEN B, XI WQ, et al.Drug-drug interactions and disease status are associated with irinotecan-induced hepatotoxicity: a cross-sectional study in Shanghai[J]. Journal of Clinical Pharmacology, 2022, 62(9): 1160-1169.
[13] National Center for Clinical Research of Infectious Disease. Expect consensus on the diagnosis and treatment of intrahepatic cholestasis (2021 edition)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2022, 30(2): 137-146.
[14] TIAN YJ, WANG JP, LEI XP, et al.Effect of ursodeoxycholic acid on acute liver injury induced by antitumor drugs and its effect on T lymphocyte subsets[J]. Chinese Hepatology(肝脏), 2020, 25(1): 73-75.
[15] CHEN J.Observation on the effect of adenosylmethionine combined with ursodeoxycholic acid in the treatment of cholestatic drug-induced liver injury[J]. Zhejiang Practical Medicine(浙江实用医学), 2015, 20(4): 239-240.
[16] LI RR, LI M, GOU Y, et al.Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(5): 505-510.
[17] Medical Affairs Department of the National Health Commission. Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2023, 14(4): 706-733.
[18] FOLPRECHT G, GRUENBERGER T, BECHSTEIN W, et al.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)[J]. Annals of oncology, 2014, 25(5): 1018-1025.
[19] FANG WT, GU YH.Medication options for colorectal cancer with complications[J]. Chinese Journal of Colorectal Diseases(Electronic Edition)(中华结直肠疾病电子杂志), 2018, 7(5): 420-430.
[20] RAYMOND E, BOIGE V, FAIVRE S, et al.Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction[J]. Journal of Clinical Oncology, 2002, 20(21): 4303-4312.
[21] Guangdong Pharmaceutical Association.Expert consensus on the clinical application and adverse reaction management of platinum drugs[J]. Pharmacy Today(今日药学), 2019, 29(9): 577-585.
[22] DOROSHOW JH, SYNOLD TW, GANDARA D, et al.Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group[J]. Seminars in Oncology, 2003, 30(4 Suppl 15): 14-19.

1例伊立替康致结肠癌患者急性肝损伤的药学监护

Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	潘知玉, 朱健, 于亚南, 刘骏, 姜燕华, 钱真真, 吴广, 王忠, 武红莉, 荆志伟. 3010例芪蛭通络胶囊的真实世界安全性研究[J]. 中国药物警戒, 2024, 21(6): 660-665.
[2]	邵波, 徐丽丽, 朱兰, 刘硕, 万浩, 黄光瑞. 湿毒清制剂肝损伤风险分析及思考[J]. 中国药物警戒, 2024, 21(6): 666-670.
[3]	高旭, 彭金娥, 范子博, 张伟. 利福平致溶血性贫血临床特征与预后结局的系统评价[J]. 中国药物警戒, 2024, 21(6): 671-676.
[4]	阿拉腾花, 高磊, 张晓朦, 张冰. 基于蒙医药学古籍文献探析蒙药药物警戒科学内涵[J]. 中国药物警戒, 2024, 21(6): 677-682.
[5]	唐祯菊, 龙小换, 王意军, 黄愉腾, 王卫亮. 甲苯磺酸多纳非尼片致多形红斑型药疹1例分析[J]. 中国药物警戒, 2024, 21(6): 700-702.
[6]	于静, 帕拉提·热合曼, 赵婷, 冯继荣, 孙岩, 何磊. 拉考沙胺治疗4岁以下癫痫患儿疗效、安全性与血药浓度的相关性研究[J]. 中国药物警戒, 2024, 21(5): 559-562.
[7]	刘翠丽, 吴晨, 王涛. 吡拉西坦制剂安全性风险分析及思考[J]. 中国药物警戒, 2024, 21(5): 563-566.
[8]	苏小涵, 曾姣, 李雪, 刘礼鑫, 侯令密, 李金穗. 基于美国FAERS数据库的乳腺癌患者使用阿贝西利不良事件分析[J]. 中国药物警戒, 2024, 21(5): 580-586.
[9]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[10]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[11]	李少强, 孔旭东, 李朋梅. 注射用奥美拉唑钠致低钠血症1例分析[J]. 中国药物警戒, 2024, 21(4): 461-463.
[12]	伍诗琪, 闫素英, 张青霞. 艾多沙班药代动力学相互作用研究进展[J]. 中国药物警戒, 2024, 21(4): 473-480.
[13]	黄焕均, 麦嘉恒, 张云惠, 郭晨晨, 梁蔚婷. 613例抗肿瘤药物的不良反应分析[J]. 中国药物警戒, 2024, 21(3): 324-328.
[14]	刘琦, 张玉凤, 罗皓, 李歆. 106例安罗替尼临床应用的合理性与安全性分析[J]. 中国药物警戒, 2024, 21(3): 329-334.
[15]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.